Annexon Stock Today
| ANNX Stock | USD 5.10 0.04 0.78% |
Performance0 of 100
| Odds Of DistressLess than 29
|
Annexon is trading at 5.10 as of the 26th of November 2024; that is 0.78 percent decrease since the beginning of the trading day. The stock's open price was 5.14. Annexon has about a 29 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Annexon are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of July 2020 | Category Healthcare | Classification Health Care |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company was incorporated in 2011 and is headquartered in Brisbane, California. Annexon operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 106.59 M outstanding shares of which 7.77 M shares are presently shorted by private and institutional investors with about 6.77 trading days to cover. More on Annexon
Moving against Annexon Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Annexon Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | JD Esq | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAnnexon can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Annexon's financial leverage. It provides some insight into what part of Annexon's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Annexon (ANNX) is traded on NASDAQ Exchange in USA. It is located in 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005 and employs 71 people. Annexon is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 547.89 M. Annexon conducts business under Biotechnology sector and is part of Health Care industry. The entity has 106.59 M outstanding shares of which 7.77 M shares are presently shorted by private and institutional investors with about 6.77 trading days to cover.
Annexon currently holds about 177.59 M in cash with (121.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.73.
Check Annexon Probability Of Bankruptcy
Ownership AllocationThe majority of Annexon outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Annexon to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Annexon. Please pay attention to any change in the institutional holdings of Annexon as this could imply that something significant has changed or is about to change at the company.
Check Annexon Ownership Details
Annexon Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Gmt Capital Corp | 2024-06-30 | 2.9 M | |
| Adage Capital Partners Gp Llc | 2024-06-30 | 2.8 M | |
| Geode Capital Management, Llc | 2024-09-30 | 2.1 M | |
| Candriam Luxembourg S.c.a. | 2024-06-30 | 2.1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2 M | |
| State Street Corp | 2024-06-30 | 1.8 M | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1.7 M | |
| Jpmorgan Chase & Co | 2024-06-30 | 1.7 M | |
| Nuveen Asset Management, Llc | 2024-06-30 | 1.6 M | |
| Fmr Inc | 2024-09-30 | 8.6 M | |
| Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 8.4 M |
Annexon Historical Income Statement
Annexon Stock Against Markets
Annexon Corporate Management
| Shikhar MBA | Senior Commercial | Profile | |
| Arnon Rosenthal | Founder | Profile | |
| Michael MBA | Executive Officer | Profile | |
| Mirella Toro | Sec | Profile | |
| Ted Yednock | Chief VP | Profile | |
| HenkAndre MD | Senior Medicine | Profile |
Already Invested in Annexon?
The danger of trading Annexon is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Annexon is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Annexon. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Annexon is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Annexon Stock Analysis
When running Annexon's price analysis, check to measure Annexon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexon is operating at the current time. Most of Annexon's value examination focuses on studying past and present price action to predict the probability of Annexon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexon's price. Additionally, you may evaluate how the addition of Annexon to your portfolios can decrease your overall portfolio volatility.